Trial · NCT04183881
A Phase 4 Clinical Study of Brodalumab
NCT04183881, Phase 4, Completed, Kyowa Kirin Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 4 Clinical Study of Brodalumab. Trials, record NCT04183881. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04183881
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 4 Clinical Study of Brodalumab
- NCT number
- NCT04183881
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 138 participants, actual
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Interventions
- Brodalumab 210mg SC
- First posted
- 2019-12-03
- Last updated
- 2019-12-09
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and types of adverse events and adverse reactions | 28 weeks | |
| Primary | Anti-KHK4827 antibody | 28 weeks | |
| Secondary | Change in psoriasis area and severity index (PASI) compared to the data obtained before the first dose of investigational product in this study. | 28 weeks | |
| Secondary | Percent improvement in PASI | 28 weeks | |
| Secondary | PASI 50, 75, 90, and 100 | 28 weeks | |
| Secondary | Static physician's global assessment (sPGA) of "0 (clear) or 1(almost clear)" | 28 weeks | |
| Secondary | sPGA of "0 (clear)" | 28 weeks | |
| Secondary | Change in body surface area involvement (BSA) of lesion | 28 weeks | |
| Secondary | Clinical Global Impression (CGI) | 28 weeks | |
| Secondary | American College of Rheumatology (ACR) 20 | 28 weeks |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04183881
GET https://conductscience.org/api/trials/v1/NCT04183881/registered